Regencell Bioscience Holdings Limited (NASDAQ:RGC – Get Free Report)’s share price dropped 5.1% during trading on Tuesday . The company traded as low as $24.30 and last traded at $24.48. Approximately 100,662 shares were traded during mid-day trading, a decline of 67% from the average daily volume of 305,052 shares. The stock had previously closed at $25.80.
Trending Headlines about Regencell Bioscience
Here are the key news stories impacting Regencell Bioscience this week:
- Negative Sentiment: Multiple law firms, including Faruqi & Faruqi, Rosen, Glancy Prongay Wolke & Rotter, Pomerantz, and Bronstein Gewirtz & Grossman, reminded investors of a pending securities class action and the June 23, 2026 lead-plaintiff deadline. Article Title
- Negative Sentiment: Several notices highlighted allegations that Regencell Bioscience may have made misleading statements tied to its business model, including claims about a relatively small R&D budget versus a very large market valuation, which can weigh on investor sentiment. Article Title
- Negative Sentiment: One update said institutional investors may be reviewing their exposure because the company’s valuation, zero revenue, and small employee base are now being cited in connection with a DOJ investigation and litigation risk. Article Title
- Neutral Sentiment: Another headline noted short interest data, but the reported figures were effectively flat and do not appear to be a major standalone driver.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.
Regencell Bioscience Trading Up 1.7%
The stock’s 50-day simple moving average is $27.77 and its 200 day simple moving average is $25.04.
Regencell Bioscience (NASDAQ:RGC – Get Free Report) last posted its quarterly earnings data on Friday, May 8th. The company reported $0.00 earnings per share for the quarter.
Institutional Investors Weigh In On Regencell Bioscience
A number of hedge funds have recently added to or reduced their stakes in RGC. Squarepoint Ops LLC bought a new position in shares of Regencell Bioscience during the 2nd quarter worth approximately $1,701,000. BNP Paribas Financial Markets bought a new stake in shares of Regencell Bioscience in the 2nd quarter valued at $768,000. XTX Topco Ltd bought a new stake in shares of Regencell Bioscience in the 3rd quarter valued at $598,000. Bank of America Corp DE lifted its position in shares of Regencell Bioscience by 59,113.8% during the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after acquiring an additional 17,143 shares during the period. Finally, Hudson Bay Capital Management LP acquired a new position in shares of Regencell Bioscience during the 4th quarter valued at $275,000. 0.13% of the stock is currently owned by institutional investors.
About Regencell Bioscience
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
See Also
- Five stocks we like better than Regencell Bioscience
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Regencell Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regencell Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
